Ana Isabel Oviedo

Waiting for two abstracts to be presented the whole @AACR #AACR26, this is one of them Just presented, #Daraxonrasib in #mKRAS #PDAC by @EileenMOReilly #Monotherapy in the #FirstLine 38 pts ORR 47% Time on tto 7.7m PFS immature Ongoing Phase III 303 (Dara vs GemNab+/-Dara)

Here is Version 2.0 of when to hold systemic tx during RT. Updated & w 3 additional drug categories (ADCs, CDK4/6 inhibitors, PARPi). More details on newer drugs in 🧵 below. Please use this version as reference & thanks for all input/experience crowdsourcing! (1/3)

It was a design very similar to NETTER-1. Patients had to have had progression on standard dose SSA (and PLEASE - patients DO NOT fail therapy. The therapy fails the patient. How to journals like Annals of Oncology still let this wording slip through...?). The control arm was double-dose octreotide LAR which is an unexciting control therapy but still quite reasonable to use. Well designed trial but quite different population than in NETTER-1. A small minority had sbNETs, most had either pancreas or rectal. Also, more patients had chemo and targeted therapy pre-PRRT which may explain the PFS differences (control arm with short PFS). IMO, not new or exciting info but validating results, especially in different population. COMPETE should come out soon and will be interesting to compare.

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial | Nature Communications ⁦@VHIO⁩ ⁦@vallhebron⁩ ⁦@aecat_es⁩ ⁦@GrupoGetne⁩ nature.com/articles/s4146…

💉 SC pembrolizumab: real progress or just convenience? JCO commentary raises key concerns: 🔹 No efficacy gain → PK non-inferiority only 🔹 Modest real-world time savings 🔹 Fixed dosing → less flexibility, higher costs 🔹 Likely “patent hopping” ahead of biosimilars ⚖️ Are we paying more for convenience without added value? 🔗 doi.org/10.1200/JCO-25…

Now there’s some food for thought! As if the data wasn’t compelling enough… nice to see some stats wisdom at work quantifying the benefits!

More real-world data showing #FOLFIRINOX (FFX) as a potential option in digestive #NEC: Retrospective series (n=50, 66% 2nd-line & 82% later lines after platinum-etoposide) → RR 44% (39% in 2L), DCR 72%, mPFS 5.6 mo. Especially promising in colorectal NEC (RR 52%) FOLFIRINEC trial will finally clarify FFX vs platinum+etoposide in 1st line! #Neuroendocrine #GEPNEC Butt et al. J @JNE_Editor doi.org/10.1111/jne.70…

🔬📊 Metastatic CRC NEC ≠ ADC ⚠️ DCR 43% vs 74% ⚠️ PFS 2.4 vs 7.7 mo ⚠️ OS 6.7 vs 16.8 mo 💬 Platinum–etoposide clearly underperforms → time to rethink 1L 🧬 Shared genomics ≠ shared biology 🚨 Need better strategies (FOLFIRINOX/FOLFOXIRI?) 🔗 doi.org/10.1002/ijc.70…

Un repaso en 6 min sobre cáncer colorrectal para gastroenterólogos, aquí resumimos puntos principales de las guías más recientes (NCCN, ESMO)👇

Thanks to @ENETS_ORG for the invitation to speak about this challenging topic #Individualising care for #Pancreatic #NETs Not easy, but data coming to support our decisions Our work continues - join our #TumourBurdenScore validation efforts 😉

Exploratory biomarkers analyses from the phase 2 Study With paltusotine . Póster presentation @asco GI 2026 San Francisco. @Crinetics @AnaIsabelOviedo @RachelRiechelm2 @JuanOConnorA

What's next in DLL3-targeted therapy for NECs...? Maybe this... pnas.org/doi/10.1073/pn…

Presented today at @EASLnews #LiverCancerSummit 2026 #4year OS data from #TOPAZ1 with CisGemDurva for advanced #BTC 👉11.8% of patients alive at 4 years (4.3%) in the placebo arm 🧐subsequent lines of therapy, around 8% targeted - low? reflection of the time when conducted?

Cabozantinib for patients with well diff G3 NETs...? What are the data? This analysis of the ALLIANCE A021602 - CABINET trial provides some info. 24 patients w/ G3 NETs, 16 on cabo and 8 on placebo. Primary sites: Pancreas (n=12); GI tract (n=7); unknown primary (n=3); lung/ thymus (n=2). Median PFS for patients with G3 NET treated with cabozantinib was 7.9 months vs 3 months with placebo. ORR: 25% (4/16) with cabozantinib vs. 0% (0/8) with placebo. No new safety signals. @ALLIANCE_org @EileenMOReilly @adasarimd @NVijayvergiaMD erc.bioscientifica.com/view/journals/…

Is this the day you wanted to learn more about the evolving concepts in neuroendocrine neoplasm pathology including grading and subtyping...? If so, you are in luck. Three of my favorite NEN pathologists including @AurelPerren just wrote a review for you. You are a NEN enthusiast, you need to read this. link.springer.com/article/10.100…

🏥Nab-paclitaxel plus bevacizumab for metastatic extrapulmonary NEC @eClinicalMed ➡️Mainly GI primary ➡️Previosly treated (%50 at least 2line) ✅mOS: 12.8 mo ✅mPFS: 5.3 mo ✅ORR: 55% 👉thelancet.com/journals/eclin… #cancer #oncology #MedX #nec @OncoAlert @OncoThor @UGrewalMD @OncBrothers

All star team presenting on NECs at #ESMO25 today . Outstanding session. Thanks @RachelRiechelm2 @ @Juanmaoconnor @FRANCES88189587 and Halfdan Sørbye.

Can we identify those less likely to benefit from valve surgery for carcinoid heart disease? Per this Mayo Clinic study, extensive liver replacement (>75%), bone mets and severe RV dysfunction all predicted worse outcomes after surgery. Bravo, Dr. Sawma! sciencedirect.com/science/articl…

🫁 𝗦𝗼𝘀𝗽𝗲𝗰𝗵𝗮 𝗱𝗲 𝗧𝗘𝗣: ¿𝗽𝗼𝗿 𝗱𝗼́𝗻𝗱𝗲 𝗲𝗺𝗽𝗶𝗲𝘇𝗼? ⬇️⬇️⬇️⬇️ 1️⃣🔴 ¿𝗜𝗻𝗲𝘀𝘁𝗮𝗯𝗶𝗹𝗶𝗱𝗮𝗱 𝗵𝗲𝗺𝗼𝗱𝗶𝗻𝗮́𝗺𝗶𝗰𝗮? ⚠️𝙎𝙞́: estabiliza + ecocardiografía. •Disfunción VD → tratar como TEP. •Sin disfunción → buscar otro dx. ✳️𝙉𝙤: pasa a evaluación clínica. 2️⃣🧠 𝗘𝘃𝗮𝗹𝘂́𝗮 𝗽𝗿𝗼𝗯𝗮𝗯𝗶𝗹𝗶𝗱𝗮𝗱 𝗰𝗹𝗶́𝗻𝗶𝗰𝗮 (𝗣𝗧𝗣): 📊Usa Wells o score de Ginebra. 3️⃣🔹 𝗣𝗧𝗣 𝗯𝗮𝗷𝗮: ‼️Aplica PERC → si negativo, TEP descartado. 🧬Si no, usa dímero D. 4️⃣⚠️ 𝗣𝗧𝗣 𝗶𝗻𝘁𝗲𝗿𝗺𝗲𝗱𝗶𝗮/𝗮𝗹𝘁𝗮: ✳️Considera anticoagulación empírica. ➡️Dímero D → si elevado → angioTAC o V/Q. 5️⃣🩻 Imágenes: ❎𝙉𝙚𝙜𝙖𝙩𝙞𝙫𝙤 → descarta TEP. ✅𝙋𝙤𝙨𝙞𝙩𝙞𝙫𝙤 → ¡𝘁𝗿𝗮𝘁𝗮𝗿 𝗰𝗼𝗺𝗼 𝗧𝗘𝗣! 👇🏼👇🏼👇🏼👇🏼👇🏼 t.me/ClubCrit 👉 [buff.ly/ns3qz3S] #TEP #ManejoClínico #Urgencias #UCI #Enfermería #Emergencias #ClubCrit #Medicina #UCI #FOAMed #FOAMcc #MedTwitter #ICU #CriticalCare #MedEd #CuidadoCrítico #MedX #EducaciónMédica #MedIntensiva #MedXCommunity #MedicinaCrítica #MedED #CritCare #ICUManagement #MustRead #LecturaRecomendada